Publication: Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?
Issued Date
2020-01-01
Resource Type
ISSN
15469549
15469530
15469530
Other identifier(s)
2-s2.0-85091063099
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Heart Failure Reports. (2020)
Suggested Citation
Thanat Chaikijurajai, Hernan Rincon Choles, W. H.Wilson Tang Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?. Current Heart Failure Reports. (2020). doi:10.1007/s11897-020-00488-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/59282
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?
Other Contributor(s)
Abstract
© 2020, Springer Science+Business Media, LLC, part of Springer Nature. Purpose of Review: Impaired renal function may affect natriuretic peptide levels through a variety of factors and mechanisms, such as high prevalence of concomitant vascular and myocardial diseases, reduced clearance, increased risk of volume overload, and different types and solute removal techniques in the setting of dialysis. Nevertheless, accumulating evidence suggests that natriuretic peptide testing may provide insights into management of patients with chronic kidney disease (CKD) and end-stage kidney disease (ESRD) on dialysis, as they have been shown to be independently associated with morbidity and mortality. Recent Findings: Rising natriuretic peptide levels over time may identify CKD patients more likely to approach ESRD and requiring dialysis initiation. Moreover, serial natriuretic peptide measurements may also be helpful in guiding fluid management in ESRD patients on dialysis. However, since patients with CKD usually have significantly higher and more variable baseline levels of natriuretic peptides than those without CKD, traditional cut-off values may not be applicable, and individualized trajectories should be applied and interpreted in the clinical context. Summary: Routine clinical use natriuretic peptide testing in the CKD and ESRD settings still needs to be refined and individualized, yet their diagnostic and prognostic values can provide valuable insights into clinical trajectories and potential treatment responses.